Combined Role of Position Emission Tomography (PET) and Magnetoencephalography (MEG) in Nonlesional Epilepsy
|Epilepsy||Device: magnetoencephalography Device: Positron emission tomography (PET) Device: Magnetic resonance imaging||Phase 3|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
|Official Title:||Combined Role of PET and MEG in Nonlesional Epilepsy in Pediatric Population|
- The concordance rate of FDG-PET and MEG with video EEG [ Time Frame: 3 years ]
- The positive and negative predictive values of each modality and combined modalities in assessing the epileptogenic zone. [ Time Frame: 3 years ]
|Study Start Date:||March 2008|
|Study Completion Date:||June 2011|
|Primary Completion Date:||March 2011 (Final data collection date for primary outcome measure)|
MEG studies are performed using a whole-head Omega 151-channel gradiometer system.Device: Positron emission tomography (PET)
An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.Device: Magnetic resonance imaging
MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
Children with poorly controlled epilepsy are extensively investigated with various tools including MR brain, electroencephalography (EEG), magnetoencephalography (MEG) or position emission tomography (PET) scans. When MR brain does not show an abnormality, the patient is said to have nonlesional epilepsy. In these cases, it is even more crucial to be able to identify the epileptogenic zone, depending on availability of investigative tool.
Recognizing that individual modalities have limitations, the aim of this study is to determine if combining non-invasive investigations with MEG and PET, which respectively evaluate the electrical and metabolic activity of the brain, could improve the children with intractable nonlesional epilepsy with MEG and PET and compared this with invasive intracranial monitoring. The endpoint of the study being agreement on localizations of epileptogenic zone using PET and MEG individually and in combination and comparing this with invasive intracranial monitoring.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00741559
|The Hospital for Sick Children|
|Toronto, Ontario, Canada|
|Principal Investigator:||Martin Charron, MD||The Hospital for Sick Children|